StockMarketWire.com - Pharma giant AstraZeneca said a pancreatic cancer treatment, jointly developed with Merck, had been approved in the European Union.
The approval by the European Commission was based on results from a Phase III Polo trial, which were published in The New England Journal of Medicine.
It followed the recommendation for approval by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
'In the Polo trial, Lynparza nearly doubled median progression-free survival versus placebo after 1st-line chemotherapy for patients with germline BRCA-mutated metastatic pancreatic cancer,' the company said.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.